Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 88 | 2,875 | 47% |
| 2020 | 62 | 2,188 | 50% |
| 2021 | 81 | 2,616 | 53% |
| 2022 | 77 | 2,817 | 56% |
| 2023 | 93 | 3,393 | 58% |
| 2024 | 94 | 3,603 | 60% |
| 2025 from claims | – | 4,222 3,874–4,467 | 61% |
| 2026 forecast | – | 4,631 4,075–5,344 | 61% |
| 2027 forecast | – | 4,977 4,255–5,932 | 61% |
| 2028 forecast | – | 5,349 4,463–6,550 | 61% |
| 2029 forecast | – | 5,747 4,694–7,208 | 62% |
| 2030 forecast | – | 6,175 4,947–7,913 | 62% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 27% of the cases CMS names in Ohio; 57 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 64% inpatient hospital, 35% hospital outpatient, 1% office.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~4,600 | ~3,000 | ~1,600 | ~29 |
| 2027 · ~5,000 | ~3,300 | ~1,700 | ~23 |
| 2028 · ~5,300 | ~3,500 | ~1,800 | ~20 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 66% (64% in 2025), hospital outpatient about 33% (35% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 125 | 4,051+13%/yr | +13%/yr | 2.6 | 15% | 6,990 in 2030+9.5%/yr |
| Michigan | 82 | 3,065+2.7%/yr | +2.7%/yr | 3.1 | 17% | 4,880 in 2030+8.1%/yr |
| Indiana | 68 | 2,697+18%/yr | +18%/yr | 3.3 | 0% | 4,650 in 2030+9.5%/yr |
| Kansas | 56 | 2,663+15%/yr | +15%/yr | 6.0 | 5% | 4,850 in 2030+10%/yr |
| Missouri | 58 | 2,381+6.1%/yr | +6.1%/yr | 3.3 | 1% | 3,950 in 2030+8.8%/yr |
| Wisconsin | 50 | 1,796+14%/yr | +14%/yr | 2.7 | 0% | 3,250 in 2030+10%/yr |
| Minnesota | 42 | 1,476+9.6%/yr | +9.6%/yr | 2.8 | 3% | 3,650 in 2030+16%/yr |
| Nebraska | 22 | 1,071+16%/yr | +16%/yr | 3.8 | 3% | 1,730 in 2030+8.3%/yr |
| Iowa | 21 | 859+11%/yr | +11%/yr | 1.8 | 5% | 1,760 in 2030+13%/yr |
| North Dakota | 15 | 600+12%/yr | +12%/yr | 5.5 | 0% | 1,190 in 2030+12%/yr |
| South Dakota | 11 | 481+17%/yr | +17%/yr | 3.4 | 0% | 890 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 116 | 5,350−4.9%/yr | −4.9%/yr | 5.00.9× | 0% | 5,520 in 2030+0.5%/yr |
| EP ablation | 100 | 4,592+3.6%/yr | +3.6%/yr | 3.41.1× | 0% | 7,400 in 2030+8.3%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
Boston Scientific leads with 87% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 4 companies reported engagement with Ohio’s surgeons worth $312K in consulting, speaking, meals and travel tied to these products, about $3,319 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.